Post-stroke hyperglycaemia – Treatment with Exenatide in Acute Ischaemic Stroke (TEXAIS) trial

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1126070

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Raised blood glucose levels (hyperglycaemia) after a stroke is common. It reduces the efficacy of stroke treatments and results in worse outcomes. Insulin is not useful as a treatment for this as it causes frequent hypoglycaemia and does not improve clinical outcomes. Exenatide is a common diabetes drug that is simple to use and lowers blood glucose without hypoglycaemia. It will be tested in the Treatment with Exenatide in Acute Ischaemic Stroke (TEXAIS) trial.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $1,266,149.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Central Nervous System

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

diabetes | glucose metabolism | hyperglycaemia | stroke | stroke outcome

Related Links